Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

A CD3 Fusion Receptor (CD3-FR) Uniquely Enables Compatibility of Allogeneic CAR-T and -NK Cells with T Cell Engagers to Enhance Antitumor Function and Limit Antigen Escape

Eigen Peralta, Dan Lu, Mark Landon, Hui-yi Chu, Soo Park, Masanao Tsuda, Trevor Zarecki, Elena Demeester, Matthew Denholtz, Amit Mehta, Earl Avramis, Philip Chu, Jeffrey Chen, Eric Sung, Alec Witty, Tom Lee, Bahram Valamehr

Blood (2022) 140 (Supplement 1): 7429–7430.

https://doi.org/10.1182/blood-2022-169887

Published: 2022

Journal Articles

SUZ12 Participates in PNH Cloning Proliferation By Regulating Histone H3K27me3 Methylation Level

Rong Fu, Yingying Chen, Zonghong Shao, Hui Liu, Lijie Zeng, Liyan Li, Dan Lu, Zhaoyun Liu

Blood (2021) 138 (Supplement 1): 1106.

https://doi.org/10.1182/blood-2021-148546

Published: 2021

Journal Articles

Novel Method for Clonal Selection of Multiplexed Engineered CAR-T Cells Which Uniquely Demonstrate Anti-Tumor Functionality in the Tumor Microenvironment

Eigen Peralta, PhD, David Robbins, BS, Emily Carron, PhD, Matthew Denholtz, PhD, Natalie Navarrete, BS, Dan Lu, PhD, Joyee Yao, Sandeep Kothapally Hanok, Yinghui Sui, PhD, Angela Gentile, Eric Sung, Jason ORourke, PhD, Tom Lee, PhD, Daniel Shoemaker, PhD, Cokey Nguyen, PhD, Bahram Valamehr, PhD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-141506

Published: 2020

Journal Articles

Multiplexed Engineered, Off-the-Shelf T Cells Carrying Three Tumor-Associated Antigen-Targeting Modalities: CAR + Pan-Tumor Targeting TCR + CD16 Fc Receptor

Cokey Nguyen, PhD, Eigen Peralta, PhD, Chia-Wei Chang, Wen-I Yeh, PhD, Yijia Pan, PhD, Dan Lu, PhD, May Sumi, Mochtar Pribadi, PhD, Bi-Huei Yang, PhD, Eric Sung, Alec Witty, PhD, Tom Lee, PhD

Blood (2020) 136 (Supplement 1): 32.

https://doi.org/10.1182/blood-2020-141507

Published: 2020

Journal Articles

PTENα promotes neutrophil chemotaxis through regulation of cell deformability

Yunqiao Li, Yuan Jin, Bowen Liu, Dan Lu, Minglu Zhu, Yan Jin, Michael A. McNutt, Yuxin Yin

Blood (2019) 133 (19): 2079–2089.

https://doi.org/10.1182/blood-2019-01-899864

Published: 2019

Includes: Multimedia, Supplemental data

Journal Articles

Exposure-Response Analysis to Assist Selection of Dose and Treatment Duration for Polatuzumab Vedotin As a Single Agent or in Combination with Rituximab for the Treatment of B-Cell Lymphoma

Dan Lu, Jin Yan Jin, Leonid Gibiansky, William R. Gillespie, Priya Agarwal, Cheryl Jones, Yu-Waye Chu, Michael K. Wenger, Jamie Hirata, Chunze Li, Sandhya Girish

Blood (2015) 126 (23): 1525.

https://doi.org/10.1182/blood.V126.23.1525.1525

Published: 2015

Journal Articles

Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Blood (2014) 124 (21): 4457.

https://doi.org/10.1182/blood.V124.21.4457.4457

Published: 2014

Journal Articles

Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin’s Lymphoma (NHL)

Ranjana Advani, MD, Andy I. Chen, MD, PhD, Daniel Lebovic, MD, Mark W. Brunvand, MD, Andre Goy, MD, Julie E. Chang, MD, Ephraim Hochberg, Sreeni Yalamanchili, BSPharm, Robert Kahn, Dan Lu, Akiko Chai, MS, Yu-Waye Chu, Bruce D. Cheson, M.D.

Blood (2013) 122 (21): 4399.

https://doi.org/10.1182/blood.V122.21.4399.4399

Published: 2013

Journal Articles

Final Results Of a Phase I Study Of The Anti-CD79b Antibody-Drug Conjugate DCDS4501A In Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Maria Corinna Palanca-Wessels, M.D., Ph.D., Gilles Andre Salles, MD, PhD, Myron S. Czuczman, MD, Sarit E. Assouline, MD, Ian W. Flinn, MD, PhD, Laurie H. Sehn, MD, Manish Patel, MD, Randeep Sangha, Herve Tilly, MD, Ranjana Advani, MD, Olivier Casasnovas, MD, Oliver W. Press, MD, PhD, Sreeni Yalamanchili, BSPharm, Robert Kahn, Dan Lu, Akiko Chai, MS, Yu-Waye Chu, Franck Morschhauser

Blood (2013) 122 (21): 4400.

https://doi.org/10.1182/blood.V122.21.4400.4400

Published: 2013

Journal Articles

A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

Suzanne Trudel, MD, P. Leif Bergsagel, MD, Seema Singhal, M.D., Ruben Niesvizky, MD, Raymond L. Comenzo, MD, William I. Bensinger, MD, Daniel Lebovic, MD, YounJeong Choi, Dan Lu, Dorothy French, Elicia Penuel, William Ho, MD, PhD, Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 4029.

https://doi.org/10.1182/blood.V120.21.4029.4029

Published: 2012

Journal Articles

A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Ranjana Advani, MD, Daniel Lebovic, MD, Mark Brunvand, MD, Andy I. Chen, MD, PhD, Andre Goy, MD, Julie E. Chang, MD, Lauren S Maeda, MD, William Ho, MD, PhD, Robert Kahn, Dan Lu, Zheng Su, Yu-Waye Chu, Bruce D. Cheson, MD

Blood (2012) 120 (21): 59.

https://doi.org/10.1182/blood.V120.21.59.59

Published: 2012

Journal Articles

A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Maria Corinna Palanca-Wessels, M.D., Ph.D., Ian W. Flinn, MD, PhD, Laurie H. Sehn, MD, MPH, Manish Patel, MD, Randeep Sangha, MD, Myron S. Czuczman, MD, Gilles Andre Salles, MD, PhD, Franck Morschhauser, MD, Ranjana Advani, MD, Oliver W. Press, MD, PhD, William Ho, MD, PhD, Robert Kahn, Dan Lu, Zheng Su, Yu-Waye Chu, Sarit E. Assouline, MD

Blood (2012) 120 (21): 56.

https://doi.org/10.1182/blood.V120.21.56.56

Published: 2012

Journal Articles

Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody

Yiwen Li, Hongli Li, Mei-Nai Wang, Dan Lu, Rajiv Bassi, Yan Wu, Haifan Zhang, Paul Balderes, Dale L. Ludwig, Bronislaw Pytowski, Paul Kussie, Obdulio Piloto, Donald Small, Peter Bohlen, Larry Witte, Zhenping Zhu, Daniel J. Hicklin

Blood (2004) 104 (4): 1137–1144.

https://doi.org/10.1182/blood-2003-07-2585

Published: 2004

Includes: Supplemental data

NARROW

A CD3 Fusion Receptor (CD3-FR) Uniquely Enables Compatibility of Allogeneic CAR-T and -NK Cells with T Cell Engagers to Enhance Antitumor Function and Limit Antigen Escape

SUZ12 Participates in PNH Cloning Proliferation By Regulating Histone H3K27me3 Methylation Level

Novel Method for Clonal Selection of Multiplexed Engineered CAR-T Cells Which Uniquely Demonstrate Anti-Tumor Functionality in the Tumor Microenvironment

Multiplexed Engineered, Off-the-Shelf T Cells Carrying Three Tumor-Associated Antigen-Targeting Modalities: CAR + Pan-Tumor Targeting TCR + CD16 Fc Receptor

PTENα promotes neutrophil chemotaxis through regulation of cell deformability

Exposure-Response Analysis to Assist Selection of Dose and Treatment Duration for Polatuzumab Vedotin As a Single Agent or in Combination with Rituximab for the Treatment of B-Cell Lymphoma

Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin’s Lymphoma (NHL)

Final Results Of a Phase I Study Of The Anti-CD79b Antibody-Drug Conjugate DCDS4501A In Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only